Sectors

GERN
Geron Corporation
1.49
1 x 1.27
56 x 1.52
bid
ask
-
0.02
1.32%
29 @ 07:48 PM
1.48 -0.01 (0.66%)
Ytd12.88%
1y6.43%
1.45
day range
1.51
1.04
52 week range
2.01
Open1.50Prev Close1.51Low1.45High1.51Mkt Cap957.29M
Vol7.25MAvg Vol11.55MEPS-0.11P/EN/AForward P/E38.75
Beta0.59Short Ratio8.39Inst. Own76.53%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0450-d Avg1.45200-d Avg1.431yr Est4.25
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-042026-09-0.01N/AN/AN/A
2026-08-052026-06-0.01-0.02-0.01-125.23%
2026-05-062026-03-0.03-0.010.0266.67%
2026-02-252025-12-0.03-0.03N/AN/A
2025-11-052025-09-0.04-0.030.0118.19%
2025-08-062025-06-0.03-0.020.0133.33%
Upgrade / Downgrade
DateFirmActionFromTo
2025-11-05NeedhamUpgradeBuyBuy
2025-05-08ScotiabankDowngradeSector OutperformSector Perform
2025-03-12NeedhamUpgradeBuyBuy
2025-03-12HC Wainwright & Co.UpgradeNeutralNeutral
2025-02-27ScotiabankUpgradeSector OutperformSector Outperform
2025-02-27StifelUpgradeBuyBuy
Profile
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Insider Holder
DateNameRelationQuantityDescription
2025-05-08LAWLIS VIRGIL BRYAN JR.Director13.30KPurchase
2026-02-17ROBERTSON MICHELLEChief Financial Officer17.65KConversion of Exercise of derivative security
2025-02-26SAMUELS SCOTT ALANOfficer26.68KPurchase
2025-02-26SCARLETT JOHN AChief Executive Officer137.50KPurchase
2026-06-29SPIEGEL ROBERT JDirector205.81KStock Award(Grant)
2025-02-26ZIEGLER JAMESOfficer100.00KPurchase
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Blackrock Inc.49.12M76.13M7.64%
2026-06-29Soleus Capital Management, L.P.42.81M66.35M6.66%
2026-06-29RA Capital Management, L.P.42.81M66.36M6.66%
2026-06-29State Street Corporation35.86M55.58M5.58%
2026-06-29Citadel Advisors Llc29.04M45.01M4.52%
2026-06-29Vanguard Capital Management LLC27.25M42.24M4.24%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF21.74M33.69M3.38%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund20.05M31.08M3.12%
2026-06-29iShares Trust-iShares Russell 2000 ETF14.57M22.58M2.27%
2026-04-29Vanguard Explorer Fund10.17M15.77M1.58%
2026-04-29Legg Mason Partners Investment Trust-ClearBridge Small Cap Growth Fund6.32M9.79M0.98%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund5.95M9.23M0.93%
Split
SplitDate
1058 : 10002014-07-22